Nausea and vomiting associated with cancer chemotherapy: Drug management in theory and in practice

Archives of Disease in Childhood

Volumn 89, Issue 9, 2004, Pages 877-880

  Antonarakis, E S ^b   Hain, R D W ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HALOPERIDOL; IDARUBICIN; IFOSFAMIDE; LOMUSTINE; METOCLOPRAMIDE; MITOMYCIN; MITOXANTRONE; PACLITAXEL; PROCARBAZINE; STREPTOZOCIN; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NAUSEA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CHILD; DOPAMINE ANTAGONISTS; HUMANS; NAUSEA; NEOPLASMS; SEROTONIN ANTAGONISTS; VOMITING; VOMITING, ANTICIPATORY;

EID: 4444299440     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2003.037341     Document Type: Review

References (45)

1. Bender CM, McDaniel RW, Murphy-Ende K, et al. Chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 2002;6:94-102.
2. LeBaron S, Zeltzer LK, LeBaron C, et al. Chemotherapy side effects in paediatric oncology patients: drugs, age, and sex as risk factors. Med Pediatr Oncol 1988;16:263-8.
3. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9.
4. Twycross R, Back I. Nausea and vomiting in advanced cancer. European Journal of Palliative Care 1998;5(2):39-45.
5. Naylor R, Rudd J. Emesis and anti-emesis. In: Hanks G, ed. Cancer Surveys, vol. 21. Palliative medicine: problem areas in pain and symptom management. New York: Cold Spring Harbor Laboratory Press, 1994:117-35.
6. Twycross R, Wilcock A, Charlesworth S, et al. Palliative care formulary, 2nd edn. Oxford: Radcliffe Medical Press, 2002.
7. Hain R, Ballantine N, Brook L, et al. Palliative care. In: Carson D, ed. Medicines for children, 2nd edn. London: RCPCH/NPPG, 2003:G81-5.
8. Twycross R, Wilcock A. Alimentary symptoms. In: Symptom management in advanced cancer, 3rd edn. Oxford: Radcliffe Medical Press, 2002:111.
9. Davies JH, Evans BA, Jenney ME, et al. In vitro effects of combination chemotherapy on osteoblasts: implications for osteopenia in childhood malignancy. Bone 2002;31:319-26.
10. Allen JC, Gralla R, Reilly L, et al. Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy. J Clin Oncol 1985;3:1136-41.
11. Relling MV, Mulhern RK, Fairclough D, et al. Chlorpromazine with and without lorazepam as antiemetic therapy in children receiving uniform chemotherapy. J Pediatr 1993;123:811-16.
12. Nahata MC, Ford C, Ruymann FB. Pharmacokinetics and safety of prochlorperazine in paediatric patients receiving cancer chemotherapy. J Clin Pharm Ther 1992;17:121-3.
13. Graham-Pole J, Weare J, Engel S, et al. Antiemetics in children receiving cancer chemotherapy: a double-blind prospective randomized study comparing metoclopramide with chlorpromazine. J Clin Oncol 1986;4:1110-13.
14. Jurgens H, McQuade B. Ondansetron as prophylaxis for chemotherapy and radiotherapy-induced emesis in children. Oncology 1992;49:279-85.
15. McQueen KD, Milton JD. Multicenter postmarketing surveillance of ondansetron therapy in pediatric patients. Ann Pharmacother 1994;28:85-92.
16. Craft AW, Price L, Eden OB, et al. Granisetron as antiemetic therapy in children with cancer. Med Pediatr Oncol 1995;25:28-32.
17. Otten J, Hachimi-Idrissi S, Balduck N, et al. Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies. Semin Oncol 1994;21(5 suppl 9):17-19.
18. Benoit Y, Hulstaert F, Vermylen C, et al. Tropisetron in the prevention of nausea and vomiting in 131 children receiving cytotoxic chemotherapy. Med Pediatr Oncol 1995;25:457-62.
19. Miyajima Y, Numata S, Katayama I, et al. Prevention of chemotherapy-induced emesis with granisetron in children with malignant diseases. Am J Pediatr Hematol Oncol 1994;16:236-41.
20. Hahlen K, Quintana E, Pinkerton CR, et al. A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children. J Pediatr 1995;126:309-13.
21. Dick GS, Meller ST, Pinkerton CR. Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. Arch Dis Child 1995;73:243-5.
22. Jimenez M, Leon P, Gimeno J. Comparison of chlorpromazine plus dexamethasone vs ondansetron vs tropisetron in the treatment of emesis induced by highly and moderately emetogenic chemotherapy in pediatric patients with malignancies. Med Pediatr Oncol 1997;29:496.
23. Alvarez O, Freeman A, Bedros A, et al. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 1995;17:145-50.
24. Hirota T, Honjo T, Kuroda R, et al. Antiemetic efficacy of granisetron in pediatric cancer treatment. Comparison of granisetron and granisetron plus methylprednisolone as antiemetic prophylaxis. Jpn J Clin Oncol 1993;20:2369-73.
25. White L, Daly SA, McKenna CJ, et al. A comparison of oral ondansetron syrup of intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy. Pediatr Hematol Oncol 2000;17:445-55.
26. 2. Eur J Cancer 1996;32A:1744-8.
27. Stiakaki E, Savvas S, Lydaki E, et al. Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatr Hematol Oncol 1999;16:101-8.
28. Aksoylar S, Akman SA, Ozgenc F, et al. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatr Hematol Oncol 2001;18:397-406.
29. Coppes MJ, Lau R, Ingram LC, et al. Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. Med Pediatr Oncol 1999;33:99-105.
30. Coppes MJ, Yanofsky R, Pritchard S, et al. Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. J Pediatr Hematol Oncol 1999;21:274-83.
31. Mehta P, Gross S, Graham-Pole J, et al. Methylprednisolone for chemotherapy-induced emesis: a double-blind randomized trial in children. J Pediatr 1986; 108(5 pt 1):774-6.
32. Basade M, Kulkarni SS, Dhar AK, et al. Comparison of dexamethasone and metoclopramide as antiemetics in children receiving cancer chemotherapy. Indian Pediatr 1996;33:321-3.
33. Marshall G, Kerr S, Vowels M, et al. Antiemetic therapy for chemotherapy-induced vomiting: metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine alone. J Pediatr 1989;115:156-60.
34. Ekert H, Waters KD, Jurk IH, et al. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Med J Aust 1979;2:657-9.
35. Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 1987;79:946-52.
36. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-19.
37. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290-300.
38. Kris MG, Roila F, De Mulder PH, et al. Delayed emesis following anticancer chemotherapy. Supportive Care in Cancer 1998;6:228-32.
39. Dupuis LL, Lau R, Greenberg ML. Delayed nausea and vomiting in children receiving antineoplastics. Med Pediatr Oncol 2001;37:115-21.
40. Dolgin MJ, Katz ER, McGinty K, et al. Anticipatory nausea and vomiting in pediatric cancer patients. Pediatrics 1985;75:547-52.
41. Tyc VL, Mulhern RK, Barclay DR, et al. Variables associated with anticipatory nausea and vomiting in pediatric cancer patients receiving ondansetron antiemetic therapy. J Pediatr Psychol 1997;22:45-58.
42. Zeltzer LK, Dolgin MJ, LeBaron S, et al. A randomized controlled study of behavioral intervention for chemotherapy distress in children with cancer. Pediatrics 1991;88:34-42.
43. Liossi C. Clinical hypnosis in paediatric oncology: a critical review of the literature. Sleep & Hypnosis 2000;2(3):125-31.
44. Keller VE. Management of nausea and vomiting in children. J Pediatr Nurs 1995;10:280-6.
45. Foot AB, Hayes C. Audit of guidelines for effective control of chemotherapy and radiotherapy induced emesis. Arch Dis Child 1994;71:475-80.